Newport Beach, CA – August 12, 2020 – Planet DDS is pleased to announce the closing of the previously announced acquisition of Apteryx Imaging Inc. Planet DDS has acquired 100% of the Company’s outstanding common and preferred shares for CAD$0.65 per share in an all-cash transaction.
“Planet DDS and Apteryx offer substantial value propositions to the dental industry, which this acquisition will allow us to enhance moving forward,” stated Eric Giesecke, chief executive officer for Planet DDS. “Today is the beginning of a bright future for both Planet DDS and Apteryx. The entire Planet DDS family is excited to welcome Apteryx to our team.”
Founded in 2003, Planet DDS is the largest independent provider of cloud-native practice management systems to the dental industry with their Denticon software. Apteryx develops a line of award-winning imaging software technologies, including XrayVision and XVWeb, along with the VELscope oral screening device and TUXEDO intraoral sensors.
“The Planet DDS team has been instrumental in the growth of our company as a key partner for our XVWeb cloud imaging software,” stated Dr. David Gane, CEO of Apteryx Imaging. “We feel the synergies between the Planet DDS and Apteryx teams will have a very positive impact on the growth of both organizations moving forward.”
The Apteryx common shares are expected to be delisted from the TSX Venture Exchange at the close of business on or about August 13, 2020 and Apteryx will apply to cease to be a reporting issuer in British Columbia, Alberta and Ontario.
Full details of the Transaction are set out in the management information circular of the Company dated July 6, 2020 (the “Circular”). Registered Apteryx shareholders should send their completed and executed letters of transmittal and Apteryx share certificates to the depositary, Computershare Trust Company of Canada, as soon as possible in order to receive the consideration to which they are entitled to in connection with the Transaction. For those shareholders of Apteryx whose shares are registered in the name of a broker, investment dealer, bank, trust company, trust or other intermediary or nominee, they should contact such nominee for assistance in depositing their shares and should follow the instructions of such intermediary or nominee.
For more information on Planet DDS and Denticon, please visit www.planetdds.com. For details on Apteryx products and services, visit www.apteryx.com.
About Apteryx Imaging Inc.
Apteryx has provided dentists and oral health specialists with advanced diagnostic imaging software and device technologies for over 20 years. Apteryx’s proprietary technologies include XrayVision, XVWeb and XrayVision DCV imaging software solutions, the VELscope Vx Enhanced Oral Assessment and TUXEDO Intraoral Sensors.
Backed by an experienced leadership team and dedicated to a higher level of service and support, Apteryx is committed to providing dental practitioners with the best technology available by identifying and adding leading products to its growing portfolio.
For more information about Apteryx, its products and services, please visit www.apteryx.com or call 877-278-3799.
About Planet DDS and Level Equity
Planet DDS is the largest independent provider of cloud-native practice management software to the dental industry. The company’s flagship product, Denticon, is the only proven, time-tested software offering that was built from the ground up for multi-location groups in the cloud. Denticon has the largest footprint among emerging and established dental groups of any cloud software provider, allowing clients to break free from the constraints of desktop software with a comprehensive solution that includes the tools needed to standardize, centralize, and grow. All while reducing IT cost and enhancing security. Learn more about Denticon at www.planetdds.com. Planet DDS is a portfolio company of Level Equity Management, LLC (“Level Equity“).
Level Equity is a growth equity firm focused on providing capital to rapidly growing software and internet companies. The firm has raised over $1.7 billion across a series of long term committed investment partnerships with offices in New York, NY and San Francisco, CA. For more information about Level Equity, visit www.levelequity.com.
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Some of the specific forward-looking information referred to in this press release includes, but is not limited to: the timing of the delisting of the Company’s common shares and application to cease to be a reporting issuer in each of British Columbia, Alberta and Ontario.
Although the forward-looking information contained in this press release is based on what Apteryx’s management believes to be reasonable assumptions, Apteryx cannot assure investors that actual results will be consistent with such information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Email: [email protected]
Email: [email protected]
Apteryx Imaging Inc.
David Gane, CEO
Phone: 604-434-4614 ext. 227
Email: [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.